Gefitinib, a novel, orally administered agent for the treatment of cancer

Journal of Clinical Pharmacy and Therapeutics

Volumn 29, Issue 2, 2004, Pages 95-103

  Ranson, M ^a   Wardell, S ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Epidermal growth factor receptor tyrosine kinase inhibitor; Gefitinib; Iressa; Metabolism; Non small cell lung cancer; Pharmacokinetics

Indexed keywords

CARBOPLATIN; CISPLATIN; GEFITINIB; GEMCITABINE; ITRACONAZOLE; METOPROLOL; PACLITAXEL; RIFAMPICIN;

ACNE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BLOOD TOXICITY; CANCER; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; GASTROINTESTINAL TOXICITY; HUMAN; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; PRURITUS; REVIEW; SIGNAL TRANSDUCTION; SKIN TOXICITY; STEADY STATE; STOMATITIS; TREATMENT WITHDRAWAL;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; EPIDERMAL GROWTH FACTOR; HUMANS; LUNG NEOPLASMS; QUINAZOLINES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 1842633680     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2004.00543.x     Document Type: Review

References (39)

1. Arteaga CL (2002) Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist, 7(Suppl. 4), 31-39.
2. Baselga J (2002) Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist, 7(Suppl. 4), 2-8.
3. Ciardiello F, Caputo R, Bianco R et al. (2001) Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clinical Cancer Research, 7, 1459-1465.
4. Ciardiello F, Tortora G (2001) A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clinical Cancer Research, 7, 2958-2970.
5. Ciardiello F, Caputo R, Bianco R et al. (2000) Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clinical Cancer Research, 6, 2053-2063.
6. Mandal M, Adam L, Wang R-A et al. (2002) Inhibition of P21-activated kinase 1, directional cell motility and invasion of growth-factor-activated human cancer cells by the selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 ('Iressa'). Poster number 786, poster presented at San Francisco: AACR, 6-10 April.
7. Sirotnak FM, Zakowsky MF, Miller VA, Scher HI, Kris MG (2000) Potentiation of cytotoxic agents against human tumors in mice by ZD1839 (Iressa™), an inhibitor of EGFR tyrosine kinase, does not require high levels of expression of EGFR. Proceedings of the American Association of Cancer Research, 41, 482.
8. Woodburn JR, Kendrew J, Fennell M, Wakeling AE (2000) ZD1839 ('Iressa') a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TK1): inhibition of c-fos mRNA, an intermediate marker of EGFR activation, correlates with tumor growth inhibition. Proceedings of the American Association of Cancer Research, 41, 402.
9. Swaisland H, Laight A, Stafford L, Jones H, Morris C, Dane A, Yates R (2001) Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers. Clinical Pharmacokinetics, 40, 297-306.
10. Swaisland HC, Ranson M, Smith R, Leadbetter J, Laight A (2002) Clinical drug interactions with ZD1839 ('Iressa'), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Poster number 97, poster presented at Nice, France: ESMO, 18-22 October.
11. Baselga J, Rischin D, Ranson M et al. (2002) Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. Journal of Clinical Oncology, 20, 4292-4302.
12. Herbst RS, Maddox AM, Rothenberg ML et al. (2002) Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. Journal of Clinical Oncology, 20, 3815-3825.
13. Negoro S, Nakagawa K, Fukuoka M et al. (2001) Final results of a phase I intermittent dose-escalation trial of ZD1839 ('Iressa') in Japanese patients with various solid tumours. Proceedings of the American Society of Clinical Oncology, 20, 324, Abstract 1292.
14. Ranson M, Hammond LA, Ferry D et al. (2002) ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. Journal of Clinical Oncology, 20, 2240-2250.
15. Twelves C, White J, Harris A et al. (2002) The pharmacokinetics and tolerability of ZD1839 ('Iressa') in hepatically impaired patients with solid tumours. Poster number 96, poster presented at Nice, France: ESMO, 18-22 October.
16. Fukuoka M, Yano S, Giaccone G et al. (2002) Final results from a phase II trial of ZD1839 ('Iressa') for patients with advanced non-small-cell lung cancer (IDEAL 1). Proceedings of the American Society of Clinical Oncology, 21, 298a, Abstract 1188.
17. Kris MG, Natale RB, Herbst RS et al. (2002) A phase II trial of ZD1839 ('Iressa') in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2). Proceedings of the American Society of Clinical Oncology, 21, 292a, Abstract 1166.
18. 14C]-ZD1839 ('Iressa') in healthy male volunteers. Poster number 95, poster presented at Nice, France: ESMO, 18-22 October.
19. Schiller JH, Harrington D, Belani CP et al. (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. New England Journal of Medicine, 346, 92-98.
20. Massarelli E, Andre F, Liu DD et al. (2003) A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer, 39, 55-61.
21. Fossella FV, Devore R, Kerr RN et al. (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. Journal of Clinical Oncology, 18, 2354-2362.
22. Shepherd FA, Dancey J, Ramlau R et al. (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. Journal of Clinical Oncology, 18, 2095-2103.
23. Fukuoka M, Yano S, Giaccone G et al. (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology, 21, 2237-2246.
24. Herbst RS, Kies MS (2002) ZD1839 (Iressa™) in non-small cell lung cancer. Oncologist, 7(Suppl. 4), 9-15.
25. Cella D, Eton DT, Fairclough DL et al. (2002) What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. Journal of Clinical Epidemiology, 55, 285-295.
26. Douillard J-Y, Giaccone G, Horai T et al. (2002) Improvement in disease-related symptoms and quality of life in patients with advanced non-small-cell lung cancer (NSCLC) treated with ZD1839 ('Iressa') (IDEAL 1). Poster number 1195, poster presented at Orlando, FL: ASCO, 18-21 May.
27. Natale R, Skarin A, Maddox A et al. (2002) Improvement in symptoms and quality of life for advanced non-small-cell lung cancer patients receiving ZD1839 ('Iressa') in IDEAL 2. Poster number 1167, poster presented at Orlando, FL: ASCO, 18-21 May.
28. Natale RB, Zaretsky SL (2002) ZD1839 (Iressa™): what's in it for the patient? Oncologist, 7(Suppl. 4), 25-30.
29. Giaccone G, Johnson DH, Manegold C et al. (2002) A phase III clinical trial of ZD1839 ('Iressa') in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (INTACT 1). Annals of Oncology, 13(Suppl. 5), 2, Abstract 4.
30. Johnson DH, Herbst R, Giaccone G et al. (2002) ZD1839 ('Iressa') in combination with paclitaxel and carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC): results from a phase III clinical trial (INTACT 2). Annals of Oncology, 13(Suppl. 5), 127, Abstract 4680.
31. Giaccone G, Gonzalez-Larriba JL, Smit EF et al. (2001) Combination therapy with ZD1839 ('Iressa'), an orally active, selective, epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin, in patients with advanced solid tumors: promising preliminary results on tolerability, efficacy and pharmacokinetics. Poster number 553, poster presented at Miami Beach, FL, USA: AACR-NCI-EORTC, October 29-November 2.
32. Hammond LA, Figueroa J, Schwartzberg L et al. (2001) ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced colorectal cancer. Miami Beach, Florida, USA: AACR-NCI-EORTC, October 29-November 2, A549.
33. Miller K, Raabe N, Trachtenberg J, Trump D, Wilding G, Das-Gupta A (2002) ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is well tolerated in combination with mitoxantrone and prednisone in patients with hormone-refractory prostate cancer (HRPC). Annals of Oncology, 13(Suppl. 5), 91 (Abstract 327).
34. Miller VA, Johnson D, Heelan RT et al. (2001) A pilot trial demonstrates the safety of ZD1839 ('Iressa'), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with carboplatin (C) and paclitaxel (P) in previously untreated advanced non-small cell lung cancer (NSCLC). Proceedings of the American Society of Clinical Oncology, 20, 326a, Abstract 1301.
35. Soulie P, Trump D, Wilding G, Small E, Das-Gupta A (2002) ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with docetaxel and estramustine in patients with hormone-refractory prostate cancer (HRPC). Annals of Oncology, 13(Suppl. 5), 91 (Abstract 328).
36. Hillner BE, McDonald MK, Desch CE, Smith TJ, Penberthy LT, Maddox P, Retchin SM (1998) Costs of care associated with non-small-cell lung cancer in a commercially insured cohort. Journal of Clinical Oncology, 16, 1420-1424.
37. Palmer A, Brandt A (1996) The cost-effectiveness of four cisplatin-containing chemotherapy regimens in the treatment of stages III B and IV non-small cell lung cancer: an Italian perspective. Monaldi Archives for Chest Disease, 51, 279-288.
38. Leighl NB, Shepherd FA, Kwong R, Burkes RL, Feld R, Goodwin PJ (2003) Economic analysis of TAX 317: docetaxel vs. best supportive care (BSC) for second-line management of advanced non-small cell lung cancer (NSCLC). Proceedings of the American Society of Clinical Oncology, 20.
39. Douillard J-Y, Skarin AT, Baselga J et al. (2002) Improvement in disease-related symptoms and quality of life in patients with advanced non-small-cell lung cancer treated with ZD1839 ('Iressa') in IDEAL 1 and IDEAL 2. Poster number 480, poster presented at Nice, France: ESMO, 18-22 October.